Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202)

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Amifostine
Drug: Carboplatin
Drug: Taxol
Device: Radiotherapy

First Posted Date: 2005-12-28

Last Posted Date: 2017-02-01

Lead Sponsor: Mohan Suntharalingam

Target Recruit Count: 21

Registration Number: NCT00270790

Locations: 🇺🇸
University of Maryland, Baltimore, Maryland, United States

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.

Phase 3

Terminated

Conditions: NSCLC

First Posted Date: 2005-12-26

Last Posted Date: 2020-11-24

Lead Sponsor: CTI BioPharma

Target Recruit Count: 600

Registration Number: NCT00269828

Locations: 🇦🇷
Hospital General de Agudos "Dr Teodoro Alvarez", Buenos Aires, Argentina
🇦🇷
LUCEN, Cuidad Autonoma de Buenos Aires, Argentina
🇦🇷
ISIS Clinica Especializada, Urquiza, Argentina

and more 139 locations

Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery

Phase 2

Terminated

Conditions: Bladder Cancer

Interventions: Biological: bevacizumab
Drug: cisplatin
Drug: gemcitabine hydrochloride
Drug: paclitaxel
Procedure: cysectomy

First Posted Date: 2005-12-22

Last Posted Date: 2018-07-12

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 21

Registration Number: NCT00268450

Locations: 🇺🇸
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸
McLeod Regional Medical Center, Florence, South Carolina, United States

and more 1 locations

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3

Completed

Conditions: Fallopian Tube Clear Cell Adenocarcinoma
Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube Mucinous Adenocarcinoma
Fallopian Tube Serous Adenocarcinoma
Fallopian Tube Transitional Cell Carcinoma
Malignant Ovarian Mixed Epithelial Tumor
Ovarian Brenner Tumor
Ovarian Clear Cell Adenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Mucinous Adenocarcinoma

Interventions: Biological: Bevacizumab
Other: Laboratory Biomarker Analysis
Drug: Carboplatin
Other: Placebo
Drug: Paclitaxel
Other: Quality-of-Life Assessment

First Posted Date: 2005-12-07

Last Posted Date: 2019-07-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1873

Registration Number: NCT00262847

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Memorial Hospital at Easton - Shore Regional Cancer Center, Easton, Maryland, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 622 locations

Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Paclitaxel
Drug: Carboplatin
Drug: GM-CSF
Drug: Trastuzumab

First Posted Date: 2005-11-21

Last Posted Date: 2018-03-02

Lead Sponsor: Rita Sanghvi, Mehta

Target Recruit Count: 48

Registration Number: NCT00256243

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Stage IV Melanoma
Recurrent Melanoma

Interventions: Drug: carboplatin
Drug: paclitaxel
Biological: bevacizumab
Other: laboratory biomarker analysis

First Posted Date: 2005-11-21

Last Posted Date: 2013-10-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT00255762

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer

Phase 1

Completed

Conditions: Non Small Cell Lung Carcinoma

First Posted Date: 2005-11-15

Last Posted Date: 2007-12-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 44

Registration Number: NCT00252798

Locations: 🇦🇺
Research Site, East Melbourne, Victoria, Australia

Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer

Phase 3

Terminated

Conditions: Breast Neoplasm

Interventions: Drug: TOCOSOL Paclitaxel
Drug: Taxol

First Posted Date: 2005-11-09

Last Posted Date: 2009-06-04

Lead Sponsor: Achieve Life Sciences

Target Recruit Count: 821

Registration Number: NCT00251095

Locations: 🇺🇸
Stockton Hematology Oncology, Stockton, California, United States
🇺🇸
Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States
🇺🇸
Alta Bates Comprehensive Cancer Center, Berkeley, California, United States

and more 11 locations

Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: cediranib maleate
Drug: paclitaxel
Other: placebo

First Posted Date: 2005-10-27

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 296

Registration Number: NCT00245154

Locations: 🇨🇦
University Institute of Cardiology and, Quebec, Canada
🇷🇴
Oncological Institute "Ion Chiricuta", Cluj-Napoca, Romania
🇷🇴
Clinical County Hospital of Sibiu, Sibiu, Romania

and more 17 locations

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Phase 1

Completed

Conditions: Bladder Urothelial Carcinoma
Stage III Bladder Cancer AJCC v6 and v7
Stage I Bladder Cancer AJCC v6 and v7
Stage II Bladder Cancer AJCC v6 and v7

Interventions: Drug: Paclitaxel
Radiation: Radiation Therapy
Biological: Trastuzumab

First Posted Date: 2005-10-13

Last Posted Date: 2022-07-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT00238420

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Mobile Infirmary Medical Center, Mobile, Alabama, United States
🇺🇸
Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States

and more 180 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy